Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-2.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.30 0.00 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 6 |
Average Target Price | $3.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.25 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/13/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Hold |
6/13/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Hold |
6/13/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Hold |
6/13/2024 | Not Identified | Not Identified | Hold | Hold |
5/14/2024 | Piper Sandler | David Amsellem | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.